Phase I single-dose trial of MOR 103 in volunteers.
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2009
At a glance
- Drugs GSK 3196165 (Primary)
- Indications Multiple sclerosis; Rheumatoid arthritis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors MorphoSys
- 25 Jun 2009 Status changed from recruiting to completed, according to a MorphoSys media release.
- 28 Apr 2008 Status changed from initiated to recruiting, according to a Morphosys media release.
- 28 Apr 2008 The first dosing group has been treated and dosing of the second group will proceed, according to a MorphoSys media release.